UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

The utility of Martius fat pad in the repair of urogenital fistulae: review of current evidence

BJU international, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Link zum Volltext

Verfügbarkeit prüfen

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Link zum Volltext

Verfügbarkeit prüfen

14.1: Invited Paper: Heavy Metal-Free Quantum Dots for Display Applications

SID International Symposium Digest of technical papers, 2015-06, Vol.46 (1), p.168-169

2015

Link zum Volltext

Verfügbarkeit prüfen

Structural Phase Transitions and Superconductivity in Fe1+δSe0.57Te0.43 at Ambient and Elevated Pressures

Journal of the American Chemical Society, 2009-11, Vol.131 (46), p.16944-16952

2009

Link zum Volltext

Verfügbarkeit prüfen

39‐4: Invited Paper: Innovation in Heavy Metal‐Free Quantum Dot Technology

SID International Symposium Digest of technical papers, 2017-05, Vol.48 (1), p.562-564

2017

Link zum Volltext

Verfügbarkeit prüfen

20-3: Invited Paper: Utilization of Heavy Metal-Free Quantum Dots to Enhance Color Quality in Lighting Applications

SID International Symposium Digest of technical papers, 2016-05, Vol.47 (1), p.245-247

2016

Link zum Volltext

Verfügbarkeit prüfen

622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study

Annals of oncology, 2020-09, Vol.31, p.S514-S514

2020

Link zum Volltext

Verfügbarkeit prüfen

34-1: Invited Paper: Heavy Metal-Free Quantum Dots Making Inroads for Consumer Applications

SID International Symposium Digest of technical papers, 2016-05, Vol.47 (1), p.425-427

2016

Link zum Volltext

Verfügbarkeit prüfen

624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Annals of oncology, 2020-09, Vol.31, p.S515-S516

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477

2019

Link zum Volltext

Verfügbarkeit prüfen

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477-v477

2019

Link zum Volltext

Verfügbarkeit prüfen

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-03-OT3-05-03

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD5-04-PD5-04

2019

Link zum Volltext

Verfügbarkeit prüfen

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Link zum Volltext

Verfügbarkeit prüfen

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292

ESMO open, 2023-05, Vol.8 (1), p.101395, Article 101395

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD6-11-PD6-11

2018

Link zum Volltext

Verfügbarkeit prüfen

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2044-S2045

2017

Link zum Volltext

Verfügbarkeit prüfen

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

Structural Phase Transitions and Superconductivity in Fe 1+δ Se 0.57 Te 0.43 at Ambient and Elevated Pressures

Journal of the American Chemical Society, 2009-11, Vol.131 (46), p.16944-16952

2009

Link zum Volltext

Verfügbarkeit prüfen

Progress in the Development of Heavy Metal-Free Quantum Dots for Electroluminescent Displays

2018 25th International Workshop on Active-Matrix Flatpanel Displays and Devices (AM-FPD), 2018, p.1-3

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(97)

Publikationsform

Artikel
(103)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(54)
Science & Technology
(54)
Life Sciences & Biomedicine
(50)
Adult
(37)
Middle Aged
(31)
Biological And Medical Sciences
(30)
Male
(30)
Female
(29)
Neurosciences & Neurology
(29)
Space Life Sciences
(24)
Neurosciences
(22)
Medical Sciences
(21)
Aged
(16)
Clinical Neurology
(16)
Neurology
(16)
Reflex, Vestibulo-Ocular - Physiology
(10)
Fundamental And Applied Biological Sciences. Psychology
(9)
Otorhinolaryngology
(8)
Eye Movements - Physiology
(7)
Parasites
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The utility of Martius fat pad in the repair of urogenital fistulae: review of current evidence

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

14.1: Invited Paper: Heavy Metal-Free Quantum Dots for Display Applications

Structural Phase Transitions and Superconductivity in Fe1+δSe0.57Te0.43 at Ambient and Elevated Pressures

39‐4: Invited Paper: Innovation in Heavy Metal‐Free Quantum Dot Technology

20-3: Invited Paper: Utilization of Heavy Metal-Free Quantum Dots to Enhance Color Quality in Lighting Applications

622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study

34-1: Invited Paper: Heavy Metal-Free Quantum Dots Making Inroads for Consumer Applications

624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC)

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Structural Phase Transitions and Superconductivity in Fe 1+δ Se 0.57 Te 0.43 at Ambient and Elevated Pressures

Progress in the Development of Heavy Metal-Free Quantum Dots for Electroluminescent Displays

Suchergebnisse filtern